T-cell prolymphocytic leukemia (T-PLL) is a rare, usually aggressive leukemia of mature T lymphocytes. It is driven mainly by rearrangements of the TCL1A gene on chromosome 14, is diagnosed by combining a blood count, blood smear, flow cytometry, and genetic tests, and is treated first with the antibody alemtuzumab, followed where possible by a stem cell transplant. Newer targeted drugs are being studied because remissions often do not last.
What Is T-Cell Prolymphocytic Leukemia?
Prolymphocytes are medium-sized lymphocytes with a prominent nucleolus, a small dot visible inside the nucleus under the microscope. In T-PLL, a single abnormal clone of these T cells multiplies and fills the blood, marrow, spleen, liver, lymph nodes, and sometimes the skin.
T-PLL is classed as a mature (peripheral) T-cell neoplasm, meaning the cancer arises from T cells that have already left the thymus. It mostly affects older adults, with a slight male predominance, and is one of the less common hematologic cancers.
It should not be confused with its B-cell counterpart. Our article on B-cell prolymphocytic leukemia covers that separate disease, and our broader guide to prolymphocytic leukemia compares both.
Causes and Genetic Drivers
No lifestyle or environmental cause of T-PLL has been established. Instead, the disease is defined by acquired genetic changes inside the leukemic T cells.
- TCL1A rearrangement: an inversion or translocation of chromosome 14, written inv(14) or t(14;14), places the TCL1A oncogene next to the T-cell receptor gene, switching it on permanently. This is the hallmark of the disease.
- MTCP1 rearrangement: a less common translocation between chromosomes X and 14 activates a related gene, MTCP1.
- ATM loss: the ATM gene, which helps repair damaged DNA, is very frequently deleted or mutated.
- JAK-STAT pathway mutations: changes in genes such as JAK1, JAK3, and STAT5B push the cells to keep growing.
- Chromosome 8 abnormalities: extra copies of part of chromosome 8 are common.
People born with ataxia-telangiectasia, an inherited condition caused by faulty ATM, have a higher risk of T-PLL, often at a younger age. Outside that setting, T-PLL is not considered hereditary.
Symptoms and Clinical Presentation
Most people present with a rapidly rising white cell count and symptoms that develop over weeks. Typical findings include:
- Fatigue, fever, night sweats, and weight loss
- An enlarged spleen, often large, and an enlarged liver
- Swollen lymph nodes in several areas
- Skin rashes or nodules, and swelling around the eyes in some patients
- Fluid around the lungs or in the abdomen (serous effusions)
- Anemia and low platelets as the marrow becomes crowded
A minority of patients have an indolent phase, with a stable count and no symptoms. These patients may be watched closely, though the disease usually becomes active eventually.
How T-PLL Is Diagnosed
Diagnosis rests on showing a clonal population of mature T cells with the characteristic look, markers, and genetics. The table summarizes the key tests.
| Test | Typical T-PLL finding |
|---|---|
| Complete blood count | Markedly raised lymphocyte count, often very high; anemia and low platelets may be present |
| Blood smear | Medium-sized lymphocytes with a visible nucleolus and cytoplasmic blebs; a small-cell variant exists |
| Flow cytometry | Mature T-cell markers CD2, CD3, CD5, and strong CD7; CD52 highly expressed; TdT and CD1a negative |
| CD4/CD8 pattern | Most cases are CD4-positive; some co-express CD4 and CD8, and fewer are CD8 only |
| Cytogenetics and FISH | inv(14), t(14;14), or t(X;14) involving TCL1A or MTCP1 |
| TCL1 protein stain | Positive in most cases |
| Bone marrow biopsy | Infiltration by leukemic T cells; helpful but not always required |
Expert consensus criteria require a T-PLL cell count in the blood above 5 × 10⁹/L together with proof of clonality and a TCL1A or MTCP1 abnormality, or supportive features when those are absent.
Conditions to Rule Out
The main look-alikes are adult T-cell leukemia/lymphoma (linked to the HTLV-1 virus), Sézary syndrome, T-cell large granular lymphocytic leukemia, and T-cell acute lymphoblastic leukemia. Negative TdT and CD1a separate T-PLL from acute leukemia, and a negative HTLV-1 test helps exclude adult T-cell leukemia/lymphoma.
Treatment and Recent Advancements
Standard chemotherapy works poorly in T-PLL, so treatment is built around a few specific tools. A fuller discussion is in our guide to T-cell prolymphocytic leukemia causes, diagnosis, and treatment.
First-Line Therapy
Alemtuzumab, an antibody against CD52, is the preferred first treatment and produces responses in most patients. It is given intravenously, as the under-the-skin route works less well in T-PLL. Because it strongly suppresses the immune system, patients receive antiviral and antibiotic prevention and are monitored for cytomegalovirus reactivation.
Consolidation With Transplant
Remissions after alemtuzumab alone tend to be temporary. For fit patients, an allogeneic stem cell transplant (from a donor) in first remission offers the best chance of long-term disease control.
Therapies Under Investigation
Understanding of the genetics has opened new targets. Researchers are studying the BCL2 inhibitor venetoclax, JAK inhibitors that block the overactive growth signals, histone deacetylase inhibitors, and combinations of these, often alongside alemtuzumab. Their role is still being defined, so they are mainly used in clinical trials or after relapse. Purine analogs such as pentostatin have also been used, particularly in combination.
Key Takeaways
- T-PLL is a rare, usually aggressive leukemia of mature T cells, mostly in older adults.
- Rearrangement of TCL1A on chromosome 14 is its genetic hallmark, often with ATM loss.
- Diagnosis combines blood counts, smear, flow cytometry, and cytogenetics.
- Intravenous alemtuzumab followed by a donor transplant is the standard approach for eligible patients.
- Targeted drugs aimed at BCL2 and the JAK-STAT pathway are active areas of research.
Frequently Asked Questions
Is T-cell prolymphocytic leukemia curable?
Cure is difficult, but some patients who achieve remission and then undergo a donor stem cell transplant have long-term disease control. For patients who cannot have a transplant, the aim is to control the disease and maintain quality of life for as long as possible.
How is T-PLL different from CLL?
CLL is almost always a B-cell disease and often progresses slowly, while T-PLL arises from T cells and usually progresses quickly. Flow cytometry separates them reliably by showing whether the abnormal cells carry B-cell or T-cell markers.
Why is alemtuzumab used for T-PLL?
T-PLL cells carry large amounts of CD52 on their surface, the target of alemtuzumab. That makes the antibody far more effective than conventional chemotherapy in this disease.
Can T-PLL be inherited?
Generally not. The genetic changes arise in the leukemia cells during life. The exception is ataxia-telangiectasia, an inherited condition that raises the risk.
